3x Faster Analysis with Seqera to Accelerate Biomarker Discovery and Cancer Diagnostics
Read the full case study3x
faster analysis processing time
30%
reduction in operational costs
3x
increase in throughput capacity
Aim
To develop methods to identify biomarkers from liquid biopsies to enable early-stage cancer detection and diagnosis and improve cancer care outcomes at scale.Challenges
- →Large scale data processing required significant computational resources and coordination of many specialized internal tools.
- →Limited access to sufficient computational resources (memory and CPU) on demand, restricting operational scalability within the team.
- →Advanced technical expertise required to deploy and maintain complex analytical pipelines, creating a scalability ceiling.
- →Compromising on parallelization through smaller sequential jobs restricts throughput and places heavy workload on a few team members.
- →Scaling through additional EC2 instances to meet computational demands leads to increased operational costs.
— Ahmad Zyoud, Senior Bioinformatician
Solution
Nextflow
Automated, scalable pipeline orchestration and workflow management to streamline complex bioinformatics processing and reduce manual intervention.
Seqera
Seamless AWS Batch integration enabling efficient multithreading, scalability across large datasets, and simplified cloud resource management.
Fusion
Cost optimization through execution checkpoints and AWS Spot Instance interruption mitigation, delivering substantial operational savings.
Results
Utilizing Seqera, Wobble Genomics achieved a significant increase in data processing throughput capacity, 3x faster analysis turnaround times, and 30% reduction in operational costs. These improvements enabled Wobble to process significantly larger RNA datasets while dramatically reducing computational bottlenecks, creating new opportunities for therapeutic target discovery and advancing early cancer detection capabilities.
3x
Opportunity
Early cancer detection
Potential to detect early onset of cancer and other diseases through RNA abundance analysis, transforming patient care worldwide.
Improved therapeutic discovery
Reliably detecting low-abundance transcripts enables discovery of new therapeutic targets and RNA-based diagnostics.
Methodology innovation
Efficient large-scale RNA processing enables broader transcriptome data access and advances in biomarker detection.
About
Wobble Genomics is a biotechnology company specializing in long-read RNA sequencing. Its innovative Level-Up biochemical technology is designed to enhance the detection of low-abundance RNA sequences, ensuring that even the rarest signals can be accurately captured and studied. This approach allows scientists to observe and catalogue all unique full-length RNA sequences present within any biological sample, providing a more complete picture of cellular activity.
When combined with TAMA bioinformatic technology, Wobble delivers powerful optimization for identifying subtle, low-level signals. By harnessing the complexity of RNA biology, the company enables researchers to generate deeper insights and achieve greater resolution from sequencing data.
Learn more: www.wobblegenomics.com